Sinopharm Group CoSHTDY +0.18%73 5-Year Yield-on-Cost % is 5.15 as of Jul. 09, 2026, which is 33% above its 10-year median of 3.88. GuruFocus rates SHTDY with a GF Score™ of 73/100 and a GF Value™ of $13.28 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 69 Medical Distribution companies, Sinopharm Group Co ranks better than 71.01% on this metric.
Sinopharm Group Co's yield on cost for the quarter that ended in Dec. 2025 was 5.15.
The historical rank and industry rank for Sinopharm Group Co's 5-Year Yield-on-Cost % or its related term are showing as below:
SHTDY'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.99 Med: 3.88 Max: 6.43
Current: 5.15
During the past 13 years, Sinopharm Group Co's highest Yield on Cost was 6.43. The lowest was 0.99. And the median was 3.88.
SHTDY's 5-Year Yield-on-Cost % is ranked better than 71.01% of 69
companies
in the Medical Distribution industry
Industry Median: 3.28
vs SHTDY: 5.15
Sinopharm Group Co (OTCPK:SHTDY) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Sinopharm Group Co 5-Year Yield-on-Cost % Related Terms
SHTDY vs MCK, CAH, COR: 5-Year Yield-on-Cost % Comparison
For the Medical Distribution subindustry, Sinopharm Group Co's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sinopharm Group Co 5-Year Yield-on-Cost % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sinopharm Group Co's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Sinopharm Group Co's 5-Year Yield-on-Cost % falls into.
Sinopharm Group Co 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Sinopharm Group Co (SHTDY) has a 5-Year Yield-on-Cost % of 5.15 as of Jul. 09, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Sinopharm Group Co and its competitors. This is 33% above median its historical median of 3.88. Over the past decade, Sinopharm Group Co's 5-Year Yield-on-Cost % has ranged from 0.99 to 6.43. According to the industry distribution chart, Sinopharm Group Co ranks #20 out of 69 companies in the Medical Distribution industry, placing it in the top 29%.
Is Sinopharm Group Co's 5-Year Yield-on-Cost % too high?
Sinopharm Group Co's current 5-Year Yield-on-Cost % of 5.15 is 33% above median its 10-year median of 3.88. Over the past 10 years, this metric has ranged from a low of 0.99 to a high of 6.43. The Medical Distribution industry median 5-Year Yield-on-Cost % is 3.28. Sinopharm Group Co's value of 5.15 is 57% above this industry median. Based on the distribution chart, Sinopharm Group Co ranks #20 out of 69 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Sinopharm Group Co has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sinopharm Group Co's 5-Year Yield-on-Cost % compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Sinopharm Group Co ranks #20 out of 69 companies for 5-Year Yield-on-Cost %. This puts Sinopharm Group Co in the upper half of its industry. The industry median 5-Year Yield-on-Cost % is 3.28. Sinopharm Group Co's value of 5.15 is 57% above this benchmark. Historically, Sinopharm Group Co's own 5-Year Yield-on-Cost % has ranged from 0.99 to 6.43 over the past decade. While the company's 10-year median is 3.88 vs. the industry median of 3.28, Sinopharm Group Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Distribution company?
The median 5-Year Yield-on-Cost % among Medical Distribution companies is 3.28, based on 69 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sinopharm Group Co's current 5-Year Yield-on-Cost % of 5.15 is 57% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Sinopharm Group Co and its competitors. For the Medical Distribution industry, the median 5-Year Yield-on-Cost % is 3.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sinopharm Group Co's current 5-Year Yield-on-Cost % is 5.15, which is 33% above median its own 10-year median of 3.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinopharm Group Co stock overvalued right now?
Based on GuruFocus' analysis, Sinopharm Group Co (SHTDY) is currently considered Modestly Undervalued. The stock's GF Value™ is $13.28, compared to a current price of $10.88 — trading 18.1% below its estimated fair value. The current 5-Year Yield-on-Cost % is 5.15, which is 33% above median its 10-year median of 3.88 and 57% above the Medical Distribution industry median of 3.28. Sinopharm Group Co's overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Sinopharm Group Co (SHTDY), the current 5-Year Yield-on-Cost % is 5.15 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sinopharm Group Co (SHTDY) Overvalued in 2026?
Based on GuruFocus' analysis, Sinopharm Group Co stock appears to be undervalued.
The current stock price of $10.88 is trading 18.1% below its estimated GF Value™ of $13.28.
GuruFocus considers Sinopharm Group Co to be Modestly Undervalued.
Key valuation signals for SHTDY:
5-Year Yield-on-Cost %: 5.15 (33% above median its 10-year median of 3.88)
GF Value™: $13.28 vs. price of $10.88 (18.1% below fair value)
Industry Position: 57% above the Medical Distribution median (#20 of 69)
No single metric tells the full story. See the SHTDY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Founded in 2003, Sinopharm is the largest wholesaler and retailer of drugs and medical devices in China and listed on the Hong Kong Stock Exchange in 2009. It is a core subsidiary of China National Pharmaceutical Group. Sinopharm's largest operating segment is pharmaceutical distribution, making up over 70% of its total revenue by the end of 2024. In 2018, Sinopharm acquired the largest Chinese medical device distributor, China National Scientific Instruments and Materials. Now, medical device distribution accounts for over 20% of Sinopharm's total revenue. Sinopharm's downstream customers range from hospitals and other health services institutions to end-customers.
73GF Score
Get the complete analysis for SHTDY
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHTDY has been successfully added to your 